XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.86 and traded as low as $2.58. XBiotech shares last traded at $2.66, with a volume of 74,953 shares traded.
XBiotech Price Performance
The firm has a 50-day moving average of $2.85 and a 200-day moving average of $3.38. The stock has a market cap of $85.37 million, a PE ratio of -2.17 and a beta of 0.98.
XBiotech (NASDAQ:XBIT - Get Free Report) last released its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Institutional Trading of XBiotech
Several institutional investors have recently made changes to their positions in the business. Northern Trust Corp grew its position in shares of XBiotech by 15.2% during the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock worth $835,000 after purchasing an additional 27,909 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in XBiotech by 7.5% during the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock valued at $360,000 after buying an additional 6,328 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in XBiotech by 15.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after buying an additional 8,918 shares in the last quarter. Deutsche Bank AG purchased a new position in XBiotech during the 4th quarter valued at approximately $120,000. Finally, Barclays PLC grew its holdings in XBiotech by 13.9% during the 4th quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after buying an additional 3,661 shares in the last quarter. Hedge funds and other institutional investors own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Read More
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
